2024-07-17 16:47:26 ET
Summary
- VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors.
- Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unmet medical needs.
- Strategic collaborations include the Bill & Melinda Gates Foundation, Alnylam Pharmaceuticals, and Gilead Sciences.
- The company has substantial liquid resources and no financial debt, supporting a compelling valuation.
- I believe VIR is undervalued tapping into significant TAMs, making it a "strong buy."
...
Read the full article on Seeking Alpha
For further details see:
Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis